Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole? | Zendy

Audrey Le | Zendy; Dimitrios Farmakiotis | Zendy; Jeffrey J. Tarrand | Zendy; Dimitrios P. Kontoyiannis | Zendy

Open Access

Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?

Author(s) -

Audrey Le,

Dimitrios Farmakiotis,

Jeffrey J. Tarrand,

Dimitrios P. Kontoyiannis

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00631-17

Subject(s) - echinocandin , fluconazole , fungemia , candida glabrata , azole , polyene , microbiology and biotechnology , medicine , echinocandins , mycosis , biology , pharmacology , antifungal , caspofungin , surgery , biochemistry

The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependentCandida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8;P = 0.003).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research